Additional Paid in Capital of Akari Therapeutics Plc from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Akari Therapeutics Plc quarterly Additional Paid in Capital in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Akari Therapeutics Plc Additional Paid in Capital for the quarter ending 30 Sep 2025 was $224,366,000.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Akari Therapeutics Plc Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $224,366,000 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $220,846,000 +$200,896,897 +1007% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q4 2024 $212,706,000 +$192,787,406 +968% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $19,949,103 30 Jun 2024 8-K 06 Sep 2024
Q4 2023 $19,918,594 +$2,699,001 +16% 31 Dec 2023 8-K 06 Sep 2024
Q4 2022 $17,219,593 31 Dec 2022 8-K 06 Sep 2024
Q4 2012 $13,199,000 +$3,363,000 +34% 31 Dec 2012 20-F/A 19 Apr 2013 2012 FY
Q4 2011 $9,836,000 31 Dec 2011 20-F/A 19 Apr 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.